Supply of products by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a framework for the regulation of therapeutic goods in Australia, ensuring they are of acceptable quality, safety, and efficacy. The Act was introduced to address the need for a cohesive legislative approach to managing the importation, supply, and advertising of therapeutic goods. The Therapeutic Goods Administration (TGA), a part of the Department of Health and Ageing, is the body responsible for the enforcement of the Act. The policy objective of the Act is to protect public health by ensuring that therapeutic goods are safe and of high quality, while also facilitating access to these goods for Australians. In a specific instance, on 7 August 2013, the delegate of the Secretary of the Department of Health and Ageing, under the authority granted by sections 14 and 14A of the Therapeutic Goods Act 1989, granted consent for the supply of VAQTA hepatitis A vaccines that did not conform to certain standards outlined in Therapeutic Goods Order (TGO) 69. This consent, provided by Merck Sharp & Dohme Australia Pty Ltd, was subject to conditions that ensured the exemption applied indefinitely but was limited to the specified part of the standard, with all other parts of the standard required to be complied with. This case highlights the Act’s flexibility in addressing specific circumstances while maintaining the overarching goal of public health protection.

Scope and Application

The Therapeutic Goods Act 1989, as amended by the notice dated 7 August 2013, provides a specific exemption under sections 14 and 14A for the supply of certain hepatitis A vaccines manufactured by Merck Sharp & Dohme Australia Pty Ltd. This exemption applies to the VAQTA hepatitis A vaccines, specifically the inactivated 50 units/1 mL and 25 units/0.5 mL injection vials, which do not conform with paragraph 3(2)(b) of Therapeutic Goods Order (TGO) 69 as they lack identification of the active ingredient. The exemption granted by the delegate of the Secretary of the Department of Health and Ageing is applicable indefinitely, but it is strictly limited to the specified part of the standard, with all other parts of TGO 69 remaining in full effect. This legislative exemption is narrowly tailored to the particular products and conditions specified, ensuring compliance with the overarching regulatory framework for therapeutic goods in Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the legal framework for regulating therapeutic goods in Australia. Sections 14 and 14A specifically address consent for the supply of goods that do not conform to specified standards. In this instance, section 14(1) empowers the delegate of the Secretary of the Department of Health and Ageing to grant consent for the supply of therapeutic goods that do not meet certain standards, while section 14A(1) specifies the conditions that may be attached to such consent. Here, section 14(1) has been applied to allow the supply of two specific hepatitis A vaccines that do not conform with the Therapeutic Goods Order (TGO) 69 concerning the identification of the active ingredient. The obligations imposed by the Act on the parties involved, particularly the manufacturer Merck Sharp & Dohme Australia Pty Ltd, include ensuring that the therapeutic goods meet all regulatory standards unless consent has been granted under section 14. The Act mandates compliance with all other aspects of TGO 69, aside from the identified non-conformity. The delegate's consent, subject to the conditions outlined in section 15(1), stipulates that the exemption applies indefinitely but is limited to the specific non-conforming aspect of the standard. Therefore, the manufacturer must still ensure that all other regulatory requirements are met for the products in question. The Therapeutic Goods Act also outlines the potential consequences for non-compliance with its provisions. While the specific section pertaining to penalties is not detailed in the provided excerpt, the Act generally includes provisions for both civil and criminal penalties for breaches. Civil penalties may include fines, while criminal penalties can include imprisonment, reflecting the seriousness of non-compliance with therapeutic goods regulations. The exact penalties would depend on the nature and severity of the breach, as well as any applicable provisions within the broader legislative framework.